Preprint Article Version 1 This version is not peer-reviewed

Single Center Based Real-World Experience on ANTI-IL 1 Biological Response Modifiers: A Case Series and Literature Review

Version 1 : Received: 24 July 2024 / Approved: 25 July 2024 / Online: 25 July 2024 (07:19:49 CEST)

How to cite: Jones, O. Y. Single Center Based Real-World Experience on ANTI-IL 1 Biological Response Modifiers: A Case Series and Literature Review. Preprints 2024, 2024072016. https://doi.org/10.20944/preprints202407.2016.v1 Jones, O. Y. Single Center Based Real-World Experience on ANTI-IL 1 Biological Response Modifiers: A Case Series and Literature Review. Preprints 2024, 2024072016. https://doi.org/10.20944/preprints202407.2016.v1

Abstract

This communication is to summarize our single center experience on applications of anti-IL-1 biologic response modifiers on autoimmune and autoinflammatory conditions in children. We present our rationale for off-label utilization of Anakinra and discuss evolving treatment paradigms that warrants further research and validation. Based on our observations and successful treatment outcomes, we advocate future multilateral efforts to liberate access to anti-IL-1 medications to control inordinate and detrimental inflammation in children.

Keywords

inflammation; IL-1; anti-IL-1 biologic response modifiers; Anakinra; Canakinumab

Subject

Medicine and Pharmacology, Immunology and Allergy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.